Batefenterol (GSK961081;TD-5959) is a novelmuscarinicreceptor antagonist andβ₂-adrenoceptoragonist; displays high affinity for hM2, hM3 muscarinic and hβ₂-adrenoceptor withK_ivalues of 1.4, 1.3 and 3.7 nM, respectively.

Batefenterol is a novel first-in-class inhaled bifunctional compound possessing both muscarinic antagonist (MA) and β₂-adrenoceptor agonist (BA) properties (MABA). In competition radioligand binding studies at human recombinant receptors, batefenterol displays high affinity for hM2 (K_i=1.4 nM), hM3 muscarinic receptors (K_i=1.3 nM) and hβ₂-adrenoceptors (K_i=3.7 nM). Batefenterol behaves as a potent hβ₂-adrenoceptor agonist (EC₅₀=0.29 nM for stimulation of cAMP levels) with 440- and 320-fold functional selectivity over hβ₁- and hβ₃-adrenoceptors, respectively^[1].

In the guinea pig bronchoprotection assay, inhaled Batefenterol produces potent, dose-dependent inhibition of bronchoconstrictor responses via MA (ED₅₀=33.9 μg/mL), BA (ED₅₀=14.1 μg/mL), and MABA (ED₅₀=6.4 μg/mL) mechanisms. Significant bronchoprotective effects of Batefenterol are evident in guinea pigs via MA, BA, and MABA mechanisms for up to 7 days after dosing^[1]. In guinea pig isolated trachea expressing native muscarinic M3 and β₂, batefenterol produces smooth muscle relaxation through a dual mechanism involving competitive antagonism of the M3 receptor (EC₅₀=50 nM) and agonism of the β₂receptor (EC₅₀=25 nM). The combined effect on both muscarinic receptors and β₂receptors is more potent than either function working alone (EC₅₀=10 nM). Batefenterol exhibits a rapid rate of clearance and short half-life^[2].

740.24

Solid

C₄₀H₄₂ClN₅O₇

743461-65-6

Room temperature in continental US; may vary elsewhere.

DMSO : ≥ 100 mg/mL(135.09 mM)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (3.38 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 2.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (3.38 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。